Join Biocytogen at SABPA Annual Conference
Biocytogen is pleased to announce our participation in the SABPA Annual Conference on October 5, 2024, in San Diego! As leaders in antibody discovery and gene-editing technologies, we are eager to connect with scientists, industry professionals, and innovators to explore the latest advancements in biotechnology. This event offers a great opportunity to discuss cutting-edge research, share insights, and explore potential collaborations that can drive future breakthroughs. We look forward to seeing you there!
What is the SABPA?
The SoCal Association for Biomedical and Pharmaceutical Advancements (SABPA) is a 501(c)(3) nonprofit organization, established in 2002 by professionals and scholars from the Chinese community in San Diego. By 2005, SABPA had expanded its presence to Orange County and Los Angeles. Today, the organization boasts over 3,500 members and subscribers, including scholars, professionals, and entrepreneurs in Southern California’s biotech and pharmaceutical industries.
Operated entirely by volunteers, SABPA thrives on team cohesion and collaboration, which have been key to its growth and success. This unique volunteer-driven structure has helped SABPA build a strong foundation, uniting members and collaborators in pursuit of its mission and fostering collective synergy within the community.
Event Overview
Date and Time: October 5, 2024, 9:00 am – 5:00 pm
Location: Hilton San Diego, Del Mar 15575 Jimmy Durante Boulevard Del Mar, CA 92014
A renowned upcoming conference on October 5th will feature influential leaders such as Sabine Hadida, Vertex site head and Breakthrough Awardee; Mark McKenna, CEO of Mirador and former Prometheus CEO; Ken Song, former CEO of RayzeBio; David Bredt, founder and CSO of Rapport; Tim Lucker, managing partner at Lilly Ventures; and Diane Simeone, director of UCSD Moores Cancer Center. Attendees can expect engaging Fireside Chats on topics like M&A and Startup Mega-Raises, insights into breakthrough innovations in drug development, and discussions on transitions from academia to industry in Neuroscience IPOs. Additional highlights include a look at cutting-edge chemoproteomics platforms revolutionizing drug discovery and the role of radiopharma in M&A. For more details and a full agenda, visit the event page to join this exceptional gathering on October 5th.
Event Schedule
| Time | Activity |
| 8:00 – 9:00 am | Breakfast and Registration / Exhibition (open all day) |
| 9:00 – 9:05 am | Welcome and Opening Remarks by Hua Gong, MD, PhD |
| 9:05 – 9:20 am | 2024 SABPA Lifetime Achievement Award presented to Shu Chien, PhD |
| 9:20 – 10:00 am | Presentation by Ken Song, PhD – “Key to Creating Opportunity for Company Success – Execution” |
| 10:00 – 10:45 am | Fireside Chat on “M&A and Start-up Mega-Raises” |
| 10:45 – 11:00 am | Coffee Break & Networking |
| 11:00 – 11:30 am | Presentation by Diane Simeone, MD |
| 11:30 – 12:00 pm | Presentation by Christopher G. Parker, PhD – “Expanding the Chemical Tractability of Human Proteome” |
| 12:00 – 1:30 pm | Lunch Break – Lunch and Learn workshops |
| 1:30 – 2:15 pm | 2024 San Diego BioPharma Achievement Award Presentation by Sabine Hadida, PhD |
| 2:15 – 2:45 pm | Presentation by David Bredt, MD, PhD – “Getting a Handle on Neurotherapeutics by Targeting Receptor Associated Proteins” |
| 2:45 – 3:05 pm | Sponsor Presentation by Chunying Song, PhD – “Overcoming Bispecific Antibody Development Challenges” |
| 3:05 – 3:20 pm | Coffee Break & Networking |
| 3:20 – 4:50 pm | Panel Discussion – “Business Development and Fundraising at Different Stages of a Biotech Life Cycle” |
| 4:50 – 5:00 pm | Closing Remarks by Yi Liu, PhD |
| 5:00 pm | Networking Reception (Sponsored by Gracell) |
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the at SABPA Annual Conference in in San Diego!
